CLINICAL PHARMACOLOGY, SAFETY, AND EFFECTS OF ANTI-IL-23 ANTIBODY AMG 139

(1) Amgen Inc.

(2) Nucleus Network Ltd and Centre for Clinical Studies

(3) Auckland Clinical Studies Ltd

(4) CMAX and Royal Adelaide Hospital

(5) QPharm Pty Ltd

(6) Christchurch Clinical Studies Trust Ltd

(7) Comprehensive Clinical Research

(8) Oklahoma Foundation for Digestive Research



This item was part of the IBD II session at UEG Week 2013

This item can be cited as: United European Gastroenterology Journal; 2013: 1 (Supplement 1) A378

You may be interested in:

AZATHIOPRINE ACHIEVES MUCOSAL HEALING IN PATIENTS WITH EARLY-ONSET CROHN’S DISEASE
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
REAL TIME EVALUATION USING CONTRAST ENHANCED ULTRASOUND IN COMPLICATED CROHN’S DISEASE PATIENTS
English, Clinical aspects, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
PROTEIN CARBONYLATION PROFILE IN PATIENTS WITH ULCERATIVE COLITIS: A COMPARATIVE PROTEOMIC STUDY
English, Aetiology / Causes, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013

Categorisation:

  • Clinical Specialty
    • 'IBD-ology'
  • Diagnosis and Management
    • Medical management
  • Disease
    • Inflammatory bowel disease
  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2013